PVI
STRO icon

Pura Vida Investments’s Sutro Biopharma STRO Stock Holding History

Pura Vida Investments’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,141
Closed -$254K – 160
2022
Q4 		$254K Buy
+3,141
New +$218K 0.01% 176

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Pura Vida Investments's STRO Position: Q1 2023 in Review

Pura Vida Investments sold out of Sutro Biopharma (STRO) in Q1 2023, closing a stake of 3,141 shares — an estimated $254K sold.

Pura Vida Investments first reported a position in STRO in Q4 2022 and held it in 1 quarter. The position peaked at $254K in Q4 2022. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

  • Pura Vida Investments reported no remaining Sutro Biopharma position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 3,141 Sutro Biopharma shares in Q1 2023, an estimated $254K.
  • Pura Vida Investments first reported a position in Sutro Biopharma in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Sutro Biopharma position peaked at $254K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.